Position in AZN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$29,323,458
New position
Shares Held
148,684
first reported quarter
Ownership
0.010%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Balyasny Asset Management L.P. holds $901,802,235 across 14 Drug Manufacturers - General names. AZN ranks #6 (3.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
10,471,388 | $294,036,575 | |
| 2 | MRK |
Merck & Co., Inc.
|
1,812,608 | $218,038,616 | |
| 3 | JNJ |
Johnson & Johnson
|
600,849 | $146,871,529 | |
| 4 | BIIB |
Biogen Inc.
|
650,046 | $119,172,933 | |
| 5 | SNY |
Sanofi
|
833,780 | $40,171,520 | |
| 6 | AZN |
Astrazeneca PLC
This page
|
148,684 | $29,323,458 | |
| 7 | LLY |
ELI LILLY & Co
|
17,835 | $16,404,097 | |
| 8 | NVO |
Novo Nordisk A S
|
383,146 | $14,080,615 |
All Filings in AZN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $29,323,458 | 148,684 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||